<DOC>
	<DOCNO>NCT01135212</DOCNO>
	<brief_summary>The purpose clinical study evaluate compare efficacy safety Fimasartan ( 60mg / 120mg ) Candesartan ( 8mg ) patient mild moderate hypertension .</brief_summary>
	<brief_title>The Clinical Study Evaluate Efficacy Safety Fimasartan Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>A randomized , double-blind , Candesartan control , parallel group comparison clinical study evaluate antihypertensive efficacy safety Fimasartan patient mild moderate hypertension Approximately 288 patient enrol 10 center South Korea . This study plan 5 visit 14 week ( placebo run-in period 2 week , treatment period 12 week ) . All subject agree participate study give write informed consent voluntary assess exclusion inclusion criterion receive investigational product ( placebo ) screen visit . During 14 day placebo run-in period , subject stop previous anti-hypertension drug . After 2 week , subject assess final eligibility randomize one 3 group ( Fimasartan 60mg , Fimasartan 120mg , Candesartan 8mg ) baseline visit . Subjects take physical laboratory test receive investigational product per 4weeks treatment period ( 12weeks ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>1 . Subjects agree participate study submit write informed consent 2 . Subjects age 19 75 year 3 . Mild moderate essential hypertension subject measure 90mmHg , less 110mmHg sit diastolic blood pressure ( SiDBP ) baseline ( day 0 ) . 4 . Subjects consider understand study , cooperative , able followedup whole study period . 1 . Severe hypertension patient ; 110mmHg SiDBP and/or 180 mmHg Sitting systolic blood pressure ( SiSBP ) 2 . Patients secondary hypertension 3 . Patients significant investigation abnormal renal function ( Creatinine upper limit normal ) , abnormal liver function ( AST , ALT 2 time upper normal ) , moderate fatty lever need medication 4 . Patients hypotension sign symptom 5 . Patients surgical medical disease able affect absorption , distribution , metabolism , excretion 6 . Patients severe insulin dependent uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , regimen change oral hypoglycemic agent , use insulin ) 7 . Patients severe heart disease , ischemic heart disease within 6months , peripheral vascular disease , Percutaneous Transluminal Coronary Angiography ( PTCA ) , Coronary Artery Bypass Graft ( CABG ) 8 . Patients significant ventricular tachycardia , atrial fibrillation , atrial flutter significant arrhythmia 9 . Patients hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve mitral valve disease 10 . Patients severe cerebrovascular disease 11 . Patients waste disease , autoimmune disease , connective tissue disease present and/or previous . 12 . Patients know severe malignancy retinopathy 13 . Patients hepatitis B C HIV positive reaction 14 . Patients story evidence alcohol drug abuse within 2years 15 . Patients measure mean difference mean blood pressure arm SiDBP 10mmHg SiSBP 20mmHg screen baseline visit 16 . Patients history allergic reaction angiotensin II antagonist 17 . Patients chronic inflammation disease need chronic inflammation therapy 18 . Childbearing breastfeed woman 19 . Female plan become pregnancy possibility pregnancy n't prevent conception acknowledge method 20 . Patients take medicine within 12 week screen visit go progress clinical trial 21 . Subject judge unsuitable participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ARB</keyword>
	<keyword>Fimasartan</keyword>
</DOC>